Compare Johnson & Johnson (JNJ) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Rockwell Automation — how do they compare? Johnson & Johnson trades at $248.08 (market cap $598.96B), while Rockwell Automation trades at $463.2 (market cap $51.04B). The key difference: Johnson & Johnson is far larger — about 11.7× Rockwell Automation's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | ROK | |
|---|---|---|
Market Cap | $598.96B | $51.04B |
Volume | 6,156,228 | — |
Sector | Health | Industrials |
52-Week High | $267.24 | $495.08 |
52-Week Low | $164.36 | $328.67 |
Enterprise Value | $631.90B | $54.67B |
Dividend Yield | 2.15% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Rockwell Automation (ROK) trades at $459.09, down 0.6% on the day, with a neutral technical signal despite bullish moving averages. The company maintains strong profitability with 48.9% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include partnerships in nuclear automation and recognition as a Global Lighthouse facility, positioning ROK for AI infrastructure growth.
ROK presents a mixed outlook with premium valuation metrics (P/E 48) offset by consistent earnings beats and AI-driven growth potential. Key risks include cyclical industrial exposure and competitive pressures, while analyst consensus at $471.71 suggests modest upside from current levels with 31% buy ratings indicating cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
